Europe Malaria Treatment Market

The Europe malaria treatment market was valued at US$ 451.69 million in 2022 and is expected to reach US$ 3,060.97 million by 2030; it is estimated to grow at a CAGR of 27.0% from 2022 to 2030.

Extending Pipeline of New Drugs and Vaccines Drive Europe Malaria Treatment Market

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.

A few antimalarial that are under clinical development are mentioned in the table below:

Malaria Drugs/Vaccine/Compounds Under Clinical Development

Source: Company Website, The Insight Partners Analysis

Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

Europe Malaria Treatment Market Overview

According to a surveillance report by ECDC, France reported the highest number of malaria cases in 2020. In 2020, France reported 1,007 confirmed malaria cases. Nearly all the cases reported by EU/EEA countries in 2020 were diagnosed in people traveling to France from other countries; these mostly included individuals linked to travel routes from West Africa. In France, P. falciparum is responsible for almost all severe cases and deaths in travelers. Many research organizations are working toward developing new approaches to eliminate malaria in France. For example, teams at the Institut Pasteur are dedicated to malaria research aiming to develop vaccines. This research is vital in finding new ways of fighting malaria. The Institute Pasteur is also taking part in a major European program named EVIMalaR, which involves 17 research institutes and universities from 7 European countries, and partners from 3 African countries. Such collaborative efforts toward malaria elimination are driving the growth of the malaria treatment market in France.

Europe Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Malaria Treatment Market Segmentation

The Europe malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the Europe malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The generic drugs segment held the largest market share in 2022.

In terms of route of administration, the Europe malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022.

By distribution channel, the Europe malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on country, the Europe malaria treatment market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. France dominated the Europe malaria treatment market share in 2022.

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd are some of the leading players operating in the Europe malaria treatment market.   

Europe Malaria Treatment Market Strategic Insights

Europe Malaria Treatment Market Segmentation Analysis

Europe Malaria Treatment Market Report Highlights

Europe Malaria Treatment Report Scope

Europe Malaria Treatment Market Country and Regional Insights